markets

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Summarized from All Financial Services & Investing

Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, closing its first trading session well above its offering price.

The Shanghai-rooted biotech priced its initial public offering at $17.00 per share, only to see the stock close the day at $28.50 — a gain of roughly 68 percent that signals strong early investor appetite for its immunology-focused pipeline.

Read more Inverse Anthropic ETFs Give Traders Bearish Options on ANT Stock →

The company is a portfolio company of Qiming Venture Partners, one of the prominent venture capital firms with deep ties to China's life sciences ecosystem. The listing marks a notable cross-border capital markets transaction at a time when Chinese biotech firms have faced scrutiny in accessing U.S. public markets.

Windward Bio's focus on immunology places it in one of the more competitive and closely watched sectors in biopharma, where clinical-stage companies regularly attract significant speculative interest on listing day. Whether the opening-day premium holds will depend on upcoming clinical data readouts and broader market conditions for small-cap biotechs.

Continue reading at All Financial Services & Investing.

Frequently Asked Questions

Q.What is Windward Bio's Nasdaq ticker symbol?

Windward Bio trades on Nasdaq under the ticker symbol WWB.

Q.What price did Windward Bio set for its IPO?

Windward Bio priced its initial public offering at $17.00 per share, and shares closed at $28.50 on the first day of trading.

Q.Who is the primary backer of Windward Bio?

Windward Bio is a portfolio company of Qiming Venture Partners, a venture capital firm with significant involvement in China's life sciences sector.

More in markets →